Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors

Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors

The haem enzyme indoleamine 2,3-dioxygenase 1 (IDO1) catalyses the rate-limiting step in the kynurenine pathway of tryptophan metabolism and plays an essential role in immunity, neuronal function, and ageing. Expression of IDO1 in cancer cells results in the suppression of an immune response, and th...

Full description

Bibliographic Details
Main Authors: Ute F. Röhrig, Somi Reddy Majjigapu, Pierre Vogel, Aline Reynaud, Florence Pojer, Nahzli Dilek, Patrick Reichenbach, Kelly Ascenção, Melita Irving, George Coukos, Olivier Michielin, Vincent Zoete
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Journal of Enzyme Inhibition and Medicinal Chemistry
Subjects:
Cancer immunotherapy
structure-based drug design
tryptophan metabolism
X-ray crystallography
Online Access:https://www.tandfonline.com/doi/10.1080/14756366.2022.2089665

Internet

https://www.tandfonline.com/doi/10.1080/14756366.2022.2089665

Similar Items